300015 爱尔眼科
2025/03 - 三个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入6,026,14015.97%20,982,89420,367,15716,109,94715,000,809
减:营业总成本4,570,69313.66%16,628,94215,113,23312,152,47810,986,823
    其中:营业成本3,132,56616.59%10,886,54910,021,9757,980,3897,211,887
               财务费用41,921-32.32%214,29873,6286,655106,444
               资产减值损失----(187,757)(383,606)(95,464)(217,209)
公允价值变动收益3,323-207.97%334,398(79,423)(356,890)(448,391)
投资收益28-98.46%213,22046,52343,910141,116
    其中:对联营企业和合营企业的投资收益--------(3)(59)
营业利润1,435,63016.40%4,824,9174,947,9473,534,5003,493,998
利润总额1,404,12016.76%4,594,2824,551,0193,335,0563,147,755
减:所得税费用237,6013.22%858,153895,023646,059677,852
净利润1,166,51919.96%3,736,1303,655,9962,688,9972,469,903
减:非控股权益116,76360.09%180,074297,124164,766146,559
股东净利润1,049,75616.71%3,556,0563,358,8722,524,2312,323,344

市场价值指针
每股收益 (元) *0.11416.39%0.3850.3640.2790.334
每股派息 (元) *----0.1600.1500.1000.120
每股净资产 (元) *2.34210.98%2.2212.0212.3232.092
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容